The Effect of Virtual Reality Distraction on Anxiety, Pain, and Satisfaction in Patients Undergoing Cardiac Catheterization in Palestine (VR during Cath)

November 10, 2026 updated by: Murad Abdalkareem Husen Jkhlab, Arab American University (Palestine)

The Effect of Virtual Reality Distraction on Anxiety, Pain, and Satisfaction in Patients Undergoing Cardiac Catheterization in Palestine: A Randomized Controlled Clinical Trial

This randomized controlled trial evaluated the effect of immersive virtual reality (VR) distraction on procedural anxiety, pain, and patient satisfaction among adult patients undergoing cardiac catheterization.

Patients undergoing cardiac catheterization often experience significant anxiety and pain, which can negatively affect procedural outcomes and overall patient satisfaction. Immersive virtual reality has emerged as a promising non-pharmacological nursing intervention to mitigate procedural distress.

Participants were randomized into two groups: an intervention group receiving immersive VR distraction prior to and during the catheterization procedure, and a control group receiving standard nursing care. Procedural anxiety, pain intensity, and overall satisfaction were assessed using validated measurement instruments to determine the efficacy of the intervention.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background:

Cardiac catheterization is a widely performed invasive diagnostic and therapeutic procedure. Despite its clinical safety, patients frequently experience high levels of pre-procedural and intra-procedural anxiety and physical pain, which can induce hemodynamic instability and reduce patient satisfaction.

Study Design and Setting:

This study was conducted as a single-center, parallel-group, randomized controlled clinical trial at An-Najah National University Hospital in Nablus, Palestine.

Methods & Procedure:

A total of 92 eligible adult patients scheduled for cardiac catheterization were enrolled and randomly allocated (1:1) to either:

  1. VR Intervention Group: Received immersive virtual reality distraction (using a head-mounted display presenting relaxing virtual environments) delivered before and during the catheterization procedure alongside standard care.
  2. Control Group: Received standard peri-procedural nursing care.

Outcomes & Measurements:

Primary Outcome: Procedural anxiety measured before and after the intervention using a validated anxiety scale. Procedural pain intensity measured via the Numeric Rating Scale (NRS) and overall patient satisfaction assessed post-procedure.

Ethical Considerations:

Ethical approval was granted by the Institutional Review Board at Arab American University (R-2026/A/82/N). All participants provided written informed consent prior to enrollment.

Study Type

Interventional

Enrollment (Actual)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nablus
      • Nablus, Nablus, Palestinian Territories, P400
        • An-Najah National University Hospital (NNUH)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults ≥ 18 years undergoing elective diagnostic or interventional cardiac catheterization.
  • Able to understand and provide consent in Arabic.
  • No contraindications to VR (e.g., severe motion sickness, uncontrolled epilepsy).

Exclusion Criteria:

  • Emergency cardiac catheterization.
  • Cognitive impairments that might obstruct participation.
  • Severe visual or auditory impairments incompatible with VR use.
  • History of significant adverse reactions to VR.
  • Previous participation in a VR intervention study related to cardiac procedures
  • A documented history of an anxiety disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Group

Patients in this group received standard peri-procedural nursing and medical care before the cardiac catheterization procedure without virtual reality distraction.

Standard clinical and nursing care during cardiac catheterization without virtual reality intervention.

Experimental: VR Intervention Group

VR Intervention Group patients in this group received immersive virtual reality (VR) distraction using a head-mounted display presenting relaxing virtual environments before the cardiac catheterization procedure, alongside standard care.

Experimental VR Intervention Group Patients in this group received immersive virtual reality (VR) distraction using a head-mounted display presenting relaxing virtual environments before the cardiac catheterization procedure, alongside standard care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
State Anxiety Measured by the State-Trait Anxiety Inventory, State Anxiety Subscale (Form Y-1)
Time Frame: Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

State anxiety was measured using the Arabic version of the State-Trait Anxiety Inventory, State Anxiety Subscale (Form Y-1), a 20-item self-report questionnaire. Total scores range from 20 (minimum) to 80 (maximum); higher scores indicate greater anxiety (a worse outcome). The between-group difference in change from baseline was assessed at the pre-procedural assessment (immediately after the 15-minute virtual reality session in the intervention group, or after an equivalent routine waiting period in the control group) and at the post-procedural assessment.

Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)
Pain Intensity Measured by the Numeric Rating Scale
Time Frame: Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

Pain intensity was measured using an 11-point Numeric Rating Scale. Scores range from 0 (no pain, minimum) to 10 (worst possible pain, maximum); higher scores indicate greater pain intensity (a worse outcome).

Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)
Satisfaction With Nursing Care Measured by the Patient Satisfaction With Nursing Care Quality Questionnaire
Time Frame: Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

Satisfaction with nursing care was measured using the Arabic version of the Patient Satisfaction With Nursing Care Quality Questionnaire. Each of the 17 items is rated from 1 (poor) to 5 (excellent), and the score is the mean of the items, ranging from 1 (minimum) to 5 (maximum); higher scores indicate greater satisfaction (a better outcome).

Baseline (on admission, before group allocation), pre-procedure (30 to 60 minutes before cardiac catheterization), and post-procedure (within 30 minutes after completion of cardiac catheterization)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2026

Primary Completion (Actual)

October 20, 2026

Study Completion (Actual)

October 20, 2026

Study Registration Dates

First Submitted

November 6, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 13, 2026

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • VR-Cardiac-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly shared to protect patient privacy and confidentiality in accordance with the institutional review board approvals and informed consent agreements.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.